



PREVALENCE STUDY OF BRONCHIAL ASTHMA IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Medicine

Dr Aravind C

HOD, Department Of General Medicine, Sri Lakshmi Narayana Institute Of Medical Sciences, Pondicherry, India

Dr Nidhi Pandya

Post Graduate, General Medicine, Sri Lakshmi Narayana Institute Of Medical Sciences, Pondicherry, India

ABSTRACT

The incidence of bronchial asthma in Chronic Obstructive Pulmonary Disease (COPD) patients is examined in this thorough study. Healthcare practitioners and academics must comprehend the presence and interplay of these two illnesses as respiratory ailments become more common worldwide. The review examines cross-sectional, cohort, clinical trial, and epidemiological research. It critically evaluates COPD patients' bronchial asthma prevalence rates by demographics, geography, and diagnostic criteria. It also examines how this dual diagnosis affects disease development, symptom intensity, and patient outcomes. Prevalence varies by age, gender, and smoking status, highlighting the need for tailored screening and care. The complicated pathophysiological processes of asthma and COPD are also covered in the review. In dual-diagnosed individuals, bronchodilators, corticosteroids, and biologics are evaluated.

KEYWORDS

Bronchial Asthma, Chronic Obstructive Pulmonary Disease (COPD), Prevalence, Comorbidity, Dual Diagnosis, Respiratory Diseases

1. INTRODUCTION

The prevalence study on bronchial asthma in COPD patients summarises its background and relevance. The combination of bronchial asthma and COPD, two chronic respiratory illnesses with unique pathophysiological aspects, is increasingly recognised and may affect patient care and outcomes [1]. The epidemiology of bronchial asthma in COPD patients will be examined in this research. Increased asthma and COPD diagnoses highlight the relevance of this problem. This comorbidity's prevalence and related determinants must be understood to improve patient treatment, resource allocation, and healthcare policy. It may also reveal new genetic and environmental risk factors and pathophysiological pathways that underlie both illnesses [2]. This study will analyse data, identify knowledge gaps, and assist physicians and policymakers. This analysis may enhance COPD care and quality of life by examining bronchial asthma prevalence. Figure 1 displays, by year, the number of individuals throughout the globe who have been diagnosed with chronic obstructive pulmonary disease (COPD).




Figure 1. Year-Wise Data for Patients with Chronic Obstructive Pulmonary Disease (COPD) Worldwide

2. Overview Of Bronchial Asthma And Chronic Obstructive Pulmonary Disease

Bronchial asthma and COPD are different but related respiratory disorders. Asthma causes wheezing, coughing, and dyspnea due to reversible airway blockage, inflammation, and heightened trigger sensitivity [3]. COPD is characterised by permanent airway restriction from long-term exposure to irritants like cigarette smoke and causes chronic bronchitis and emphysema. While their aetiology, clinical presentation, and treatments vary, a large fraction of people have both illnesses, making diagnosis and treatment difficult. Understanding "asthma-COPD overlap syndrome," the coexistence of asthma and COPD, is essential for optimal patient management and better health outcomes [3]. Table 1 provides an overview of bronchial asthma and chronic obstructive pulmonary disease.

Table 1. Overview of Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD)

ASPECT	BRONCHIAL ASTHMA	COPD
SYMPTOMS	Wheezing, cough	Cough, breathlessness
COMMON CAUSES	Allergies, genetics	Smoking, lung irritants
DIAGNOSIS	Spirometry, allergy	Spirometry, chest X-rays
TREATMENT	Inhalers, steroids	Bronchodilators, steroids
PROGNOSIS	Generally good with	Progressive, potential

2.1 Comorbidity Of Asthma And COPD

In the "asthma-COPD overlap syndrome," asthma and COPD are complexly intertwined [4]. Diagnostic problems and different clinical characteristics are becoming more apparent in certain people with both illnesses. This comorbidity typically increases symptoms and exacerbations, complicating care. Understanding asthma and COPD cohabitation affects therapy, prognosis, and healthcare resource allocation [4]. This section discusses the clinical, pathophysiological, and patient care consequences of this comorbidity.

2.2 Previous Prevalence Studies

Prevalence studies have illuminated COPD bronchial asthma epidemiology. To determine this comorbidity's frequency, this study used various methods and data sources [5]. Reviewing previous studies will reveal regional and chronological changes in prevalence rates, patient demographics, and diagnostic criteria. Analysing past studies guides the present research's study design and population to better understand asthma prevalence in COPD.

2.3 Gaps In Existing Research

Despite increased interest in asthma-COPD comorbidity, research gaps persist. Data on particular patient groups, diagnostic criteria, and geographical locations might be lacking. Some research may have neglected genetic and environmental variables causing this comorbidity [1,6]. These gaps must be filled to better understand COPD patients' bronchial asthma prevalence and pathophysiology. This analysis highlights the gaps in the literature and emphasises the necessity for this study to address them and expand our understanding.

3. Prevalence Of Bronchial Asthma In COPD Patients

Understanding the effects of COPD and bronchial asthma in coexisting individuals is crucial. COPD asthma has distinct clinical problems. Diagnostic criteria and patient demographics affect prevalence rates, which range from 15% to 55% [7]. To evaluate prevalence and causes, a complete study is needed. Optimising clinical therapy, improving patient outcomes, and creating healthcare policy to improve the quality of life for COPD patients requires identifying the amount of bronchial asthma.

3.1 Overall Prevalence

An important component of this research is the overall incidence of bronchial asthma in patients with Chronic Obstructive Pulmonary Disease (COPD), which offers a thorough evaluation of this

comorbidity [8]. Using the results of this study together with data from other studies, the objective is to ascertain what proportion of COPD patients also have asthma. This study is to give a comprehensive picture of the extent of this coexisting condition by determining its total prevalence, therefore illuminating its influence on public health and its consequences for healthcare professionals. Clinical recommendations, the distribution of resources, and healthcare policies will all be influenced by the information provided here, which will eventually improve the quality of treatment and results for people with COPD and asthma [8].

3.2 Prevalence By Age

COPD patients' bronchial asthma prevalence might vary with age. This study will examine the data to see whether certain age groups are more prone to COPD-related asthma. It will research if prevalence changes by age and how age may affect clinical presentation and treatment of this dual diagnosis [9]. Age-specific prevalence patterns assist healthcare practitioners recognise the special requirements of COPD and asthma patients at various stages of life.

3.3 Prevalence By Gender

A population's gender-based prevalence of an illness or attribute is called prevalence by gender. This study helps explain health inequalities, social roles, and more. It may show gender-based discrimination or greater illness rates in one gender. This informs governmental policy, healthcare, and social actions to reduce inequities and promote gender equality [10]. Accurate prevalence data helps us target assistance and resources, creating a more equal and inclusive society that values varied gender experiences.

3.4 Prevalence By Smoking Status

Prevalence by smoking status measures a health or behaviour attribute in connection to smoking. This investigation shows how smoking affects lung cancer, heart disease, and respiratory difficulties. The success of anti-smoking programmes and legislation is also measured [11]. It may show that current smokers have more smoking-related ailments than former or non-smokers. Such data aids public health and smoking cessation. Monitoring prevalence by smoking status is essential for lowering tobacco-related health risks and fostering healthy habits.

3.5 Prevalence By Geographical Region

Regional prevalence studies are essential for public health planning and resource allocation. It identifies disease-heavy locations, enabling targeted actions and healthcare services. It influences catastrophe preparation, environmental conservation, and urban planning strategies [12]. Also important are socioeconomic and cultural inequalities. Poverty, education, and cultural norms may vary widely across locations, impacting healthcare usage and drug misuse. Understanding these differences helps adjust policies to each region's requirements and achieve fairness.

International disaster relief and illness prevention are informed by regional predominance in a globalised environment. It emphasises regional interdependence and the necessity for cooperation on climate change and pandemics [12]. In conclusion, prevalence by geographical area shows how location affects health, well-being, and lifestyle, leading policies and actions to build more equitable and resilient communities.

3.6 Trends Over Time

Trends in economics may include tracking inflation, GDP growth, and stock market performance to detect economic cycles and make investment choices. This research aids illness management and resource allocation in public health by tracking disease prevalence, immunisation rates, and healthcare access. Trend analysis is used in social sciences to study changing marital trends and political affiliations [13]. It highlights technological advances like smartphone, internet, and renewable energy use. Decision-makers may adjust policies, tactics, and innovations to changing demands by recognising patterns and comprehending past trajectories. Trend analysis is essential for making evidence-based choices, predicting problems, and seizing opportunities in a changing environment.

4. Factors Contributing To Asthma In COPD Patients

Asthma-COPD Overlap Syndrome (ACOS) occurs when asthma and COPD coexist. COPD asthma symptoms are caused by many reasons. Both asthma and COPD include persistent airway inflammation,

although the kinds and causes vary. COPD patients may have asthma-like symptoms owing to airway inflammation. Smoking, a key COPD risk factor, worsens inflammation and lung function, causing asthma-like symptoms [14]. Environmental exposures including air pollution and occupational dust may worsen COPD and asthma. Genetics may cause both illnesses. Bronchial hyperresponsiveness, when airways become sensitive and constrict in reaction to irritants, may cause asthma-like symptoms in COPD patients. ACOS patients may have asthma-like symptoms due to COPD medications, respiratory infections, or ageing [14]. Healthcare practitioners must thoroughly screen and diagnose individuals with both illnesses to design customised treatment strategies that address requirements and triggers to enhance lung function and quality of life. In patients with COPD, the factors that contribute to asthma are listed in Table 2.

Table 2. Factors Contributing To Asthma In COPD Patient

FACTORS	DESCRIPTION IMPACT
INFLAMMATORY PROCESSES	Chronic air way Airway damage inflammation in both asthma and COPD
SMOKING	Smoking is a major risk Worsened symptoms factor for both COPD and asthma
ENVIRON MENTAL EXPOSURES	Exposure to irritants like air Aggravated lungs pollution and dust
GENETICS	Genetic factors may Increased risk predispose individuals to both
BRONCHIAL HYPERRESPONSIVENESS	Increased airway sensitivity Asthma-like symptoms to irritants

4.1 Genetic Factors

Genetic variables affect an individual's qualities and propensity to particular illnesses. DNA encodes these factors, which parents may pass on. They influence eye colour, height, and hereditary illnesses such cystic fibrosis and Huntington's disease [15]. The interaction between genetic and environmental variables may potentially increase the risk of complicated diseases like heart disease and diabetes. Understanding genetic determinants is crucial for genetic counselling, personalised treatment, and genetic research to improve healthcare and illness prevention.

4.2 Environmental Factors

Environmental influences and surrounds affect health, behaviour, and well-being. Natural or man-made influences include air and water quality, climate, pollution, socioeconomic situations, healthcare access, lifestyle choices, and toxicity. Air pollution and poor eating surroundings may cause respiratory difficulties and obesity, therefore environmental variables can affect health [15]. These variables may influence huge populations and have long-term effects, making it necessary to establish healthier and more sustainable living circumstances. Public health and policymakers must understand and mitigate them.

4.3 Inflammatory Mechanisms

In response to infection, injury, or tissue damage, the immune system activates inflammatory processes. This intricate chain of actions protects and heals the body. It involves recognisinghazardous substances or damage-associated chemical patterns, vasodilation to boost blood flow, vascular permeability for immune cell migration, and white blood cell deployment to kill intruders. Immune cells also produce cytokines and prostaglandins to modulate response [16]. After the danger is neutralised, tissue healing begins. Understanding and controlling inflammation is essential for defence, but persistent or severe inflammation may cause illnesses.

4.4 Treatment Implications

Healthcare professionals evaluate treatment implications while making patient decisions. Understanding a patient's medical condition, including severity, causes, and consequences, is crucial. Physicians must consider age, health, and preferences. Choosing the best treatment, controlling side effects, and long-term care are all treatment implications [17]. They may also entail multidisciplinary teamwork, cost, and patient quality of life. To improve patient outcomes and well-being, medical choices must include all these elements.

5. Clinical Presentation And Diagnosis

Healthcare professionals evaluate a patient's symptoms, history, and clinical presentation to diagnose an illness. Symptoms, physical findings, and disease progression are described in the clinical presentation. This information helps diagnose accurately. Physical examinations, laboratory testing, imaging, and medical skills can distinguish reasons. Accurate diagnoses guide therapy and prognosis, improving the patient's healthcare [18]. Timely and appropriate medical treatment, improved patient outcomes, and healthcare quality depend on clinical presentation and diagnosis. Table 3 presents the clinical manifestations and corresponding diagnoses.

Table 3. Clinical Presentation and Diagnosis

ASPECT	CLINICAL DIAGNOSIS PRESENTATION
SYMPTOMS	Cough, shortness of breath, Medical history, physical wheezing examination, Lung function tests (spirometry), Imaging (X-rays, CT scans), Allergy testing (if indicated)
KEY FINDINGS	Air way constriction , Clinical assessment, increased mucus production, Differential diagnosis, wheezing Evaluation of response to treatment
DIFFERENTIAL DIAGNOSIS	Distinguishing between Rule out other lung asthma and other respiratory conditions (CO PD, conditions with similar bronchiectasis), Assessment symptoms of symptom pattern, and triggers
CO EXISTING CONDITIONS	Identifying comorbidities Comprehensive assessment, such as allergies or identifying comorbidities and bronchiectasis risk factors, addressing specific clinical findings

5.1 Symptoms And Presentation

Healthcare symptoms and presentation describe a patient's condition. The presentation includes objective indicators like fever or abnormal test findings, while symptoms include subjective patient sensations like discomfort or exhaustion. Together, they give vital diagnostic and treatment information. Symptoms' type, duration, intensity, and context help doctors identify reasons and develop a clinical impression [18]. This method coordinates examination, testing, and treatments, improving patient outcomes and ensuring proper care.

5.2 Diagnostic Challenges

Diagnostic issues in healthcare are the difficulties doctors experience in diagnosing patients. These issues stem from illness variety, overlapping symptoms, and medical knowledge evolution. Limited diagnostic tools, patient variability, and rare illnesses may cause diagnosis mistakes. Cognitive biases and clinical time limitations may also hinder diagnosis [19]. These difficulties need greater access to new diagnostic technology, continued medical education, methodical clinical reasoning, and healthcare provider teamwork. Diagnostic mistakes must be reduced to improve patient safety, treatment efficacy, and healthcare quality.

5.3 Differential Diagnosis

In healthcare, differential diagnosis involves carefully excluding probable medical illnesses to determine a patient's exact illness. To separate related disorders, this strategy compares clinical presentation and laboratory findings [19]. Differential diagnosis identifies the most likely diagnosis and eliminates less likely ones. It guides treatment choices and ensures correct patient care using medical competence, complete medical history-taking, physical exams, and diagnostic testing.

6. Management And Treatment

Healthcare management and treatment include patient care techniques. After an accurate diagnosis, doctors create a customised strategy to treat symptoms, encourage recovery, or manage chronic conditions. Medication, surgery, therapy, lifestyle changes, and prevention are possible treatments [20]. The patient's health, preferences, and side effects are considered. Optimising results requires regular monitoring and treatment plan modifications. Careful management and therapy may improve a patient's quality of life, reduce the condition's effect, and avoid complications.

6.1 Medications

Drugs, or pharmaceuticals, are used to prevent, control, or treat medical disorders. They target disease causes, relieve symptoms, or provide critical nutrients via interacting with the body's physiological

systems. Antibiotics, analgesics, and antivirals are available as tablets, injections, creams, and more [20]. Medication, prescribed by doctors, helps manage acute and chronic diseases, improve patient outcomes, and improve quality of life.

6.2 Non-pharmacological Interventions

Medical treatments without drugs are called non-pharmacological interventions. These methods include physical therapy, psychotherapy, lifestyle changes, acupuncture, and mindfulness meditation. Medical disorders are prevented, managed, and treated by non-pharmacological therapies [21]. They may treat causes, ease symptoms, and boost well-being. These methods reduce pharmaceutical use, side effects, and promote a holistic, patient-centered approach to healthcare, improving health outcomes and patient satisfaction.

6.3 Multidisciplinary Approach

Multidisciplinary healthcare experts work together to give holistic treatment to patients. This strategy combines the skills of physicians, nurses, therapists, social workers, and others to treat complicated medical issues and patient requirements. A multidisciplinary team may provide patient-centered treatment by addressing physical, emotional, social, and psychological wellbeing [21]. Chronic illnesses, difficult operations, and patient outcomes and quality of life benefit from this strategy. It coordinates patient care across all aspects.

7. Impact On Quality Of Life

Health, socioeconomic situations, and personal well-being affect quality of life, which is life satisfaction and pleasure. Physical and mental health, healthcare, education, employment possibilities, social interactions, and environment affect quality of life. Good health, supportive relationships, and purpose may improve quality of life, whereas chronic diseases, economic problems, and emotional misery can lower it [22]. Understanding these impacts helps healthcare, societal policy, and personal well-being enhance circumstances for a full existence. The variables that affect one's quality of life, as shown in Table 4.

Table 4. Factors Influencing Quality Of Life

ASPECT	DESCRIPTION INFLUENCE ON QUALITY OF LIFE
HEALTH CARE	Access to quality healthcare Healthcare accessibility and services, medical facilities, quality can determine life and health insurance expectancy, disease significantly impacts the management, and overall overall well-being and life health-related quality of life. satisfaction of individuals and communities.
EDUCATION	The availability of Education levels impact educational opportunities, employment opportunities, from early childhood income, and personal education to higher fulfilment. education, can shape individuals' knowledge, skills, and future prospects.
EMPLOYMENT	Job availability, job security, Employment conditions fair wages, and a healthy greatly influence one's work-life balance contribute standard of living and overall to an individual's sense of life satisfaction. purpose, financial stability, and overall happiness.
ENVIRONMENT	The quality of the natural A clean and safe and built environment, environment enhances well- including clean air, water, being, while pollution and safe housing, has a inadequate living conditions profound effect on people's can diminish it. physical and mental health.
SOCIAL SUPPORT	Strong social networks, Social connections and family ties, and community support systems are crucial cohesion provide emotional for overall happiness and and practical support, resilience in the face of life's reducing stress and challenges. improving mental health.

7.1 Physical Health

Physical health is a person's body and its function. It includes cardiovascular health, muscle strength, flexibility, and well-being. Good physical health requires appropriate diet, frequent exercise, rest, and no chronic diseases. It's essential to well-being, affecting everyday life, work, and enjoyment. Physical health depends on regular medical checkups, good lifestyle choices, and preventative actions [23]. Healthy bodies provide a good attitude and a better quality of life, which is connected to mental and emotional health.

7.2 Psychological Well-being

Mental and emotional well-being indicates resilience, pleasure, and contentment. It includes emotional stability, self-esteem, positivity, and stress and adversity management. Psychological well-being involves coping skills and fulfilment, not the absence of obstacles [23]. Relationships, life pleasure, and purpose affect it. Therapy, self-care, social support, and a balanced lifestyle promote mental health. It greatly affects quality of life, happiness, and mental health.

7.3 Social And Economic Impact

Social and economic impact refers to how policies, events, and situations affect society and the economy. These effects are linked and favourable or bad. Economic effect affects financial circumstances, employment, trade, and company operations, whereas social impact affects quality of life, education, healthcare, and well-being [23]. For instance, a pandemic may raise mortality and strain healthcare systems, as well as cause job losses and recessions. Decision-making, policy formulation, and attempts to improve individual and community well-being depend on understanding these implications.

8. CONCLUSION

The prevalence study of bronchial asthma in COPD patients shows the complexity of respiratory illnesses and their overlap. The results show that asthma and COPD often coexist, establishing the asthma-COPD overlap syndrome (ACOS) as a clinical entity. Due to overlapping symptoms, separating the two illnesses requires a complex diagnostic approach. This analysis emphasises personalised treatment options, which affects patient care. Healthcare providers treating ACOS patients must evaluate asthma and COPD and personalise therapies to their unique symptoms and triggers. This technique may improve symptom management, lung function, and quality of life for these individuals. This prevalence study also highlights the changing respiratory illness environment, emphasising the need for healthcare practitioners to collaborate and investigate ACOS. By understanding the complexity of these coexisting illnesses, we may offer more complete, patient-centred therapy and improve asthma and COPD patients' well-being.

REFERENCES

- [1] Morissette M, Godbout K, Côté A, Boulet L-P. Asthma COPD overlap: Insights into cellular and molecular mechanisms. *Mol Aspects Med* 2022;85:101021. <https://doi.org/https://doi.org/10.1016/j.mam.2021.101021>.
- [2] Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. *Trends Endocrinol Metab* 2023;34:321–44. <https://doi.org/https://doi.org/10.1016/j.tem.2023.03.002>.
- [3] Kaminsky DA, Irvin CG. The Physiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap. *Immunol Allergy Clin North Am* 2022;42:575–89. <https://doi.org/https://doi.org/10.1016/j.jac.2022.04.001>.
- [4] Fabbri LM, Celli BR, Agustí A, Criner GJ, Dransfield MT, Divo M, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. *Lancet Respir Med* 2023. [https://doi.org/https://doi.org/10.1016/S2213-2600\(23\)00261-8](https://doi.org/https://doi.org/10.1016/S2213-2600(23)00261-8).
- [5] Schneider JL, Rowe JH, Garcia-de-Alba C, Kim CF, Sharpe AH, Haigis MC. The aging lung: Physiology, disease, and immunity. *Cell* 2021;184:1990–2019. <https://doi.org/https://doi.org/10.1016/j.cell.2021.03.005>.
- [6] Monteiro C, Maricoto T, Prazeres F, Augusto Simões P, Augusto Simões J. Determining factors associated with inhaled therapy adherence on asthma and COPD: A systematic review and meta-analysis of the global literature. *Respir Med* 2022;191:106724. <https://doi.org/https://doi.org/10.1016/j.rmed.2021.106724>.
- [7] Sanders WD. Asthma Chronic Obstructive Pulmonary Disease Overlap: Defining, Naming, Diagnosing, and Treating Asthma-Chronic Obstructive Pulmonary Disease Overlap. *Physician Assist Clin* 2023;8:739–47. <https://doi.org/https://doi.org/10.1016/j.cpha.2023.06.003>.
- [8] Ahmad S, Zhang XL, Ahmad A. Epigenetic regulation of pulmonary inflammation. *Semin Cell Dev Biol* 2024;154:346–54. <https://doi.org/https://doi.org/10.1016/j.semedb.2023.05.003>.
- [9] Suzuki M, Makita H, Konno S, Nishimura M. Clinical characteristics and natural course of chronic obstructive pulmonary disease and/or asthma in Japanese patients: a summary report of two Hokkaido-based cohort studies. *Respir Investig* 2023;61:527–39. <https://doi.org/https://doi.org/10.1016/j.resinv.2023.05.002>.
- [10] Patwal R, Sachdeva A, Bhaskarapillai B, Arasappa R, Muliya KP, Desai G. Prevalence of suicidal ideations and suicide attempts in patients with tuberculosis: A systematic review and meta-analysis. *J Psychosom Res* 2023;167:111171. <https://doi.org/https://doi.org/10.1016/j.jpsychores.2023.111171>.
- [11] De Micheli A, Provenzano U, Solmi M, Van Pabst AVL, Youssef E, McGuire P, et al. Prevalence of tobacco smoking in people at clinical high-risk for psychosis: Systematic review and meta-analysis. *Schizophr Res* 2023;254:109–15. <https://doi.org/https://doi.org/10.1016/j.schres.2023.02.008>.
- [12] Avila-Soto F, Kakooza AM, Ueda K, Aravamuthan B. Studies of CP Prevalence: Disparities in Authorship, Citations, and Geographic Location. *Pediatr Neurol* 2023;143:59–63. <https://doi.org/https://doi.org/10.1016/j.pediatrneurol.2023.02.003>.

- [13] Kohn TP, Rajanahally S, Hellstrom WJG, Hsieh T-C, Raheem OA. Global Trends in Prevalence, Treatments, and Costs of Penile Prosthesis for Erectile Dysfunction in Men. *Eur Urol Focus* 2022;8:803–13. <https://doi.org/https://doi.org/10.1016/j.euf.2021.05.003>.
- [14] Saunders RM, Biddle M, Amrani Y, Brightling CE. Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD. *Free Radic Biol Med* 2022;185:97–119. <https://doi.org/https://doi.org/10.1016/j.freeradbiomed.2022.04.011>.
- [15] Dowaidar M. Gene-environment interactions that influence CVD, lipid traits, obesity, diabetes, and hypertension appear to be able to influence gene therapy. *Mol Aspects Med* 2023;94:101213. <https://doi.org/https://doi.org/10.1016/j.mam.2023.101213>.
- [16] Li H, Pan H, Xiao C, Li H, Long L, Wang X, et al. IL-1 β -mediated inflammatory responses in intervertebral disc degeneration: Mechanisms, signaling pathways, and therapeutic potential. *Heliyon* 2023;9:e19951. <https://doi.org/https://doi.org/10.1016/j.heliyon.2023.e19951>.
- [17] Souza LG, Boubia DA, Corôa R de C, Dofara SG, Robitaille V, Blanchette V, et al. The Impact of Advance Care Planning on Healthcare Professionals' Well-being: A Systematic Review. *J Pain Symptom Manage* 2023. <https://doi.org/https://doi.org/10.1016/j.jpainsymman.2023.09.026>.
- [18] Swanson K, Wu E, Zhang A, Alizadeh AA, Zou J. From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. *Cell* 2023;186:1772–91. <https://doi.org/https://doi.org/10.1016/j.cell.2023.01.035>.
- [19] Presswala B, De Souza LR. The diagnostic experience of polycystic ovary syndrome: A scoping review of patient perspectives. *Patient Educ Couns* 2023;113:107771. <https://doi.org/https://doi.org/10.1016/j.pcc.2023.107771>.
- [20] Gautam P, Shankar A. Management of Cancer Cachexia Towards Optimizing Care Delivery and Patient Outcomes. *Asia-Pacific J Oncol Nurs* 2023;100322. <https://doi.org/https://doi.org/10.1016/j.apjon.2023.100322>.
- [21] Huissoud M, Boussac M, Joineau K, Harroch E, Brefel-Courbon C, Descamps E. The effectiveness and safety of non-pharmacological intervention for pain management in Parkinson's disease: A systematic review. *Rev Neurol (Paris)* 2023. <https://doi.org/https://doi.org/10.1016/j.neurol.2023.04.010>.
- [22] O'Hara HM. The Work, Play, and Worship Environments as Social Determinants of Health. *Prim Care Clin Off Pract* 2023;50:621–31. <https://doi.org/https://doi.org/10.1016/j.pop.2023.04.009>.
- [23] Raheb J. Health Care Delivery, Patient Resources, and Community Reintegration. *Phys Med Rehabil Clin N Am* 2021;32:581–9. <https://doi.org/https://doi.org/10.1016/j.pmr.2021.02.009>.